{
  "docId": "019de071-1bdd-70bb-9c61-980d0c38b663",
  "docSlug": "a4792f18c57ea3f4ba27e696a63520de",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4148858,
  "pageNumber": 29,
  "pageCount": 40,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "other",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a three-column layout to categorize drug development projects by their biological target and therapeutic approach.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-1bdd-70bb-9c61-980d0c38b663/29",
  "deckHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663",
  "deckJsonHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663.json",
  "deckAnchorHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.67,
        "y": 0.4
      },
      "kind": "diagram",
      "text": "Tumour drivers of resistance pathway showing PI3-kinase, AKT, and mTORC1 signaling",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50d4fd38-39bd-4dff-b36f-634117f2ac31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.15,
        "x": 0.43,
        "y": 0.45
      },
      "kind": "image",
      "text": "Bispecific antibody diagram showing PD-1 and TIM3 binding sites",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d11d938d-917d-4880-a50b-fbe70aebe49e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.048,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "1. B-cell lymphoma 2. Induced myeloid leukaemia cell differentiation protein 3. Cyclin-dependent kinase 9 4. Acute myelogenous leukaemia 5. Myelodysplastic syndromes 6. Non-Hodgkin lymphoma 7. Hodgkin lymphoma 8. Peripheral T-cell lymphoma. 9. Programmed cell death protein 1. Source: AstraZeneca. Source: modified from Nature",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ed989af-463b-4da2-b26f-d79ae150e90f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.33,
        "x": 0.048,
        "y": 0.315
      },
      "kind": "table",
      "text": "Broad portfolio in cell death matrix with targets Bcl-2, Bcl-xL, BFL1, MCL1 and drugs venetoclax, AZD0466, AZD5991, AZD4573",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7d535fe-2ab3-4ff2-9985-6b72776fa368",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.675,
        "x": 0.048,
        "y": 0.202
      },
      "kind": "title",
      "text": "Emerging pipeline in main haematology indications",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db42deaf-7e78-4ec1-a164-1fa4e4bbfe77",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.675,
        "x": 0.048,
        "y": 0.148
      },
      "kind": "title",
      "text": "Haematology: projects in early development",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df6f64ab-eead-44a7-8db6-8f0fd85ee065",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "3c63d765-1912-48e8-8227-eed0298216d5",
      "evidence": "table/data: Broad portfolio in cell death matrix with targets Bcl-2, Bcl-xL, BFL1, MCL1 and drugs venetoclax, AZD0466, AZD5991, AZD4573",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 21,
      "beatId": "9bb24be0-c8c7-49aa-a526-e9fcc4794b51",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document concludes with a call to action and next steps for investors.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}